LEXICON PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $2.10 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-15.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2019-03-15
- LEXICON PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2017-12-31 was -$2.80M.
- LEXICON PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2017-09-30 was $0.00.
- LEXICON PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2017-06-30 was $0.00, a 100.00% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2017-03-31 was $2.10M, a 117.72% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2018 was $2.10M.
- LEXICON PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2017 was -$703.00K.
- LEXICON PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2016 was -$703.00K, a 111.86% decline from fiscal 2015.
- LEXICON PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2015 was $5.93M, a 315.06% increase from fiscal 2014.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month as first filed |
|---|---|---|---|---|---|
| 2018-12-31 | $2.10M 10-K · filed 2019-03-15 | ||||
| 2017-12-31 | -$2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | -$2.80M derived: sum of 2 quarters · filed 2019-03-15 | -$2.80M derived: sum of 3 quarters · filed 2019-03-15 | -$703.00K 10-K · filed 2019-03-15 | $2.10M 10-K · filed 2018-03-01 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $0.00 derived: sum of 2 quarters · filed 2018-11-01 | $2.10M 10-Q · filed 2018-11-01 | $2.10M derived: sum of 4 quarters · filed 2018-11-01 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-30 | $2.10M 10-Q · filed 2018-07-30 | $2.10M derived: sum of 3 quarters · filed 2018-07-30 | -$45.00K derived: sum of 4 quarters · filed 2018-07-30 | |
| 2017-03-31 | $2.10M 10-Q · filed 2018-05-03 | $2.10M derived: sum of 2 quarters · filed 2018-05-03 | -$45.00K derived: sum of 3 quarters · filed 2018-05-03 | $433.00K derived: sum of 4 quarters · filed 2018-05-03 | |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$2.15M derived: sum of 2 quarters · filed 2018-03-01 | -$1.67M derived: sum of 3 quarters · filed 2018-03-01 | -$703.00K 10-K · filed 2018-03-01 | |
| 2016-09-30 | -$2.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$1.67M derived: sum of 2 quarters · filed 2017-11-08 | -$703.00K 10-Q · filed 2017-11-08 | $79.00K derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-06-30 | $478.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | $1.44M 10-Q · filed 2017-08-01 | $2.23M derived: sum of 3 quarters · filed 2018-03-01 | $5.63M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-03-31 | $965.00K 10-Q · filed 2017-05-04 | $1.75M derived: sum of 2 quarters · filed 2018-03-01 | $5.15M derived: sum of 3 quarters · filed 2018-03-01 | $5.14M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2015-12-31 | $782.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $4.19M derived: sum of 2 quarters · filed 2018-03-01 | $4.17M derived: sum of 3 quarters · filed 2018-03-01 | $5.93M 10-K · filed 2018-03-01 | |
| 2015-09-30 | $3.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $3.39M derived: sum of 2 quarters · filed 2016-11-07 | $5.14M 10-Q · filed 2016-11-07 | $6.05M derived: sum of 4 quarters · filed 2017-03-06 | |
| 2015-06-30 | -$12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $1.74M 10-Q · filed 2016-08-04 | $2.65M derived: sum of 3 quarters · filed 2017-03-06 | $1.58M derived: sum of 4 quarters · filed 2017-03-06 | |
| 2015-03-31 | $1.75M 10-Q · filed 2016-05-05 | $2.66M derived: sum of 2 quarters · filed 2017-03-06 | $1.59M derived: sum of 3 quarters · filed 2017-03-06 | $2.04M derived: sum of 4 quarters · filed 2017-03-06 | |
| 2014-12-31 | $910.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | -$162.00K derived: sum of 2 quarters · filed 2017-03-06 | $286.00K derived: sum of 3 quarters · filed 2017-03-06 | $1.43M 10-K · filed 2017-03-06 | |
| 2014-09-30 | -$1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$624.00K derived: sum of 2 quarters · filed 2015-11-09 | $518.00K 10-Q · filed 2015-11-09 | -$4.77M derived: sum of 4 quarters · filed 2016-03-11 | |
| 2014-06-30 | $448.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $1.59M 10-Q · filed 2015-08-07 | -$3.70M derived: sum of 3 quarters · filed 2016-03-11 | -$2.36M derived: sum of 4 quarters · filed 2016-03-11 | |
| 2014-03-31 | $1.14M 10-Q · filed 2015-05-05 | -$4.15M derived: sum of 2 quarters · filed 2016-03-11 | -$2.81M derived: sum of 3 quarters · filed 2016-03-11 | -$2.33M derived: sum of 4 quarters · filed 2016-03-11 | |
| 2013-12-31 | -$5.29M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | -$3.95M derived: sum of 2 quarters · filed 2016-03-11 | -$3.47M derived: sum of 3 quarters · filed 2016-03-11 | -$2.21M 10-K · filed 2016-03-11 | |
| 2013-09-30 | $1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $1.81M derived: sum of 2 quarters · filed 2014-11-06 | $3.08M 10-Q · filed 2014-11-06 | $2.88M derived: sum of 4 quarters · filed 2015-03-12 | |
| 2013-06-30 | $477.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $1.74M 10-Q · filed 2014-08-07 | $1.54M derived: sum of 3 quarters · filed 2015-03-12 | $7.38M derived: sum of 4 quarters · filed 2015-03-12 | |
| 2013-03-31 | $1.26M 10-Q · filed 2014-05-08 | $1.06M derived: sum of 2 quarters · filed 2015-03-12 | $6.91M derived: sum of 3 quarters · filed 2015-03-12 | $9.07M derived: sum of 4 quarters · filed 2015-03-12 | |
| 2012-12-31 | -$200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $5.64M derived: sum of 2 quarters · filed 2015-03-12 | $7.81M derived: sum of 3 quarters · filed 2015-03-12 | $9.89M 10-K · filed 2015-03-12 | |
| 2012-09-30 | $5.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $8.01M derived: sum of 2 quarters · filed 2013-11-12 | $10.09M 10-Q · filed 2013-11-12 | $11.65M derived: sum of 4 quarters · filed 2014-03-07 | |
| 2012-06-30 | $2.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | $4.24M 10-Q · filed 2013-08-01 | $5.81M derived: sum of 3 quarters · filed 2014-03-07 | $8.15M derived: sum of 4 quarters · filed 2014-03-07 | |
| 2012-03-31 | $2.08M 10-Q · filed 2013-05-10 | $3.65M derived: sum of 2 quarters · filed 2014-03-07 | $5.99M derived: sum of 3 quarters · filed 2014-03-07 | ||
| 2011-12-31 | $1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07 | $3.90M derived: sum of 2 quarters · filed 2014-03-07 | $6.77M 10-K · filed 2014-03-07 | ||
| 2011-09-30 | $2.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $5.20M 10-Q · filed 2012-11-07 | |||
| 2011-06-30 | $2.86M 10-Q · filed 2012-08-02 | ||||
| 2010-12-31 | $2.71M 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |